UTHR up +1.16% percent right now. $UTHR High is at 126.06 and the Low 124.53 with current volume of 245,702.
Recent News posted below.
UTHR United Therapeutics Corp Recent Headline News
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Mon Nov 03, 8:02AM CST
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $130.97 on volume of 766,000 shares, below average daily volume of 998,000. United Therapeutics (NASDAQ:UTHR) is currently priced 11.2% above its average consensus analyst price target of $116.33. United Therapeutics shares have support at the 50-day moving average (MA) of $123.37 and additional support at the 200-day MA of $103.15.
UTHR: 125.11 (+0.90)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.96 (+0.59), WMGI: 27.83 (-0.12), CFN: 57.35 (+0.07), UTHR: 125.11 (+0.90), RCPT: 110.06 (+0.82), WMGIZ: 4.40 (+0.09)
Mid-Atlantic Claims $8.5 Billion Slice of $62 Billion North American Life Science Capital/MRO Investment Pie, an Industrial Info News Alert
Marketwired - Fri Oct 31, 5:15AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- There are more than 1,400 active reported Pharmaceutical-Biotech capital and maintenance (MRO) projects in North America, representing a total investment value (TIV) of nearly $62 billion. According to a recent analysis of Industrial Info's Pharmaceutical-Biotech Industry database, the Mid-Atlantic region is at the top of that investment, accounting for an $8.5 billion portion of that spending divided over 176 projects.
UTHR: 125.11 (+0.90)
Apple CEO publicly acknowledges that he's gay
By MAE ANDERSON - AP - Thu Oct 30, 6:59PM CDT
NEW YORK (AP) — Apple CEO Tim Cook's declaration that he's "proud to be gay" wasn't exactly news in Silicon Valley, where his sexual orientation was no secret. But advocates say that given Apple's immense reach and visibility, his coming-out could help change attitudes in workplaces across America.
UTHR: 125.11 (+0.90), AEO: 12.42 (-0.52), AAPL: 108.95 (-0.06)
United Therapeutics Falls on Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:02AM CDT
United Therapeutics Corporation (UTHR) incurred a third-quarter loss of 53 cents per share, missing the Zacks Consensus Estimate by a wide margin.
LCI: 51.53 (+1.36), MDT: 68.47 (+0.37), UTHR: 125.11 (+0.90), NVS: 92.52 (+0.76)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 15.92 (+14.33), BIIB: 325.66 (+4.91), AMRN: 0.84 (-0.06), UTHR: 125.11 (+0.90), NLNK: 33.72 (+1.57)
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 2.00% Loss
Comtex SmarTrend(R) - Tue Oct 28, 5:19PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 125.11 (+0.90)
Watch for United Therapeutics to Potentially Rebound After Falling 2.00% Yesterday
Comtex SmarTrend(R) - Tue Oct 28, 5:18PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 125.11 (+0.90)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 28, 12:26PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMKR: 6.38 (-0.01), XENT: 18.10 (+0.06), TRVN: 5.76 (-0.15), GLBZ: 12.40 (-0.08), SGMS: 12.61 (+0.22), ALIM: 5.00 (-0.06), UTHR: 125.11 (+0.90), SRPT: 16.17 (+0.05), WIRE: 40.57 (+0.18), REXX: 7.52 (-0.48), LMNX: 18.12 (+0.08)
United Therapeutics reports 3Q loss
Automated Insights - Tue Oct 28, 5:27AM CDT
SILVER SPRING, Md. (AP) _ United Therapeutics Corp. (UTHR) on Tuesday reported a third-quarter loss of $25.2 million.
UTHR: 125.11 (+0.90)
United Therapeutics Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 28, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2014.
UTHR: 125.11 (+0.90)
After Yesterday's Rally of 1.09% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Oct 22, 4:39PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $126.98 to a high of $131.44. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $128.69 on volume of 699,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 125.11 (+0.90)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 1.09% Gain
Comtex SmarTrend(R) - Wed Oct 22, 4:38PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $126.98 to a high of $131.44. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $128.69 on volume of 699,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 125.11 (+0.90)
United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014
PR Newswire - Tue Oct 21, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2014 financial results before market open on Tuesday, October 28, 2014.
UTHR: 125.11 (+0.90)
Creator of GeoStar and Sirius Radio, Martine Rothblatt to speak at the Church of Perpetual Life
PR Newswire - Mon Oct 20, 3:06PM CDT
Join the Church of Perpetual Life for a special presentation with Martine Rothblatt. She will be discussing the Terasem Movement which she launched in 2004. It is a transhumanist school of thought movement focused on promoting joy, diversity and the prospect of technological immortality via mind uploading and geoethical nanotechnology.
UTHR: 125.11 (+0.90)
Should Ebola Fear... Tobacco?
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 19, 11:15AM CDT
Source: Medicago In 2009, the Department of Defense's Defense Advanced Research Projects Agency, or DARPA, had a problem on its hands. The swine flu was spreading and policy makers were realizing that the current methods for producing vaccines...
RAI: 65.30 (+0.72), PM: 88.38 (+0.26), UTHR: 125.11 (+0.90), SRPT: 16.17 (+0.05), TKMR: 16.32 (-0.43), GSK: 45.20 (+0.29)
Upgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Thu Oct 16, 7:16AM CDT
United Therapeutics (NASDAQ:UTHR) was upgraded from Hold to Buy at Standpoint Research today. The stock closed yesterday at $124.04 on volume of 957,000 shares, below average daily volume of 1.1 million. Over the past year, United Therapeutics has traded in a range of $36.55 to $136.93 and closed yesterday at $124.04, 239% above that low. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 1.8%.
UTHR: 125.11 (+0.90)
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 13.24 (+0.22), UTHR: 125.11 (+0.90), PCRX: 88.02 (+2.00), HPTX: 21.54 (-0.28)
J&J Beats Q3 Earnings on Strong Drug Sales, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Oct 14, 10:27AM CDT
Johnson & Johnson's (JNJ) Pharmaceutical segment continued to deliver with new products like Olysio (HCV) putting in an impressive performance.
AGN: 195.82 (-0.18), JNJ: 108.70 (+0.50), SHPG: 200.51 (+1.93), UTHR: 125.11 (+0.90)
Shares of UTHR Up 39.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 09, 9:44AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 2 months, United Therapeutics has returned 39.74% as of today's recent price of $130.44.
UTHR: 125.11 (+0.90)
Recent News posted below.
UTHR United Therapeutics Corp Recent Headline News
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Mon Nov 03, 8:02AM CST
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $130.97 on volume of 766,000 shares, below average daily volume of 998,000. United Therapeutics (NASDAQ:UTHR) is currently priced 11.2% above its average consensus analyst price target of $116.33. United Therapeutics shares have support at the 50-day moving average (MA) of $123.37 and additional support at the 200-day MA of $103.15.
UTHR: 125.11 (+0.90)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.96 (+0.59), WMGI: 27.83 (-0.12), CFN: 57.35 (+0.07), UTHR: 125.11 (+0.90), RCPT: 110.06 (+0.82), WMGIZ: 4.40 (+0.09)
Mid-Atlantic Claims $8.5 Billion Slice of $62 Billion North American Life Science Capital/MRO Investment Pie, an Industrial Info News Alert
Marketwired - Fri Oct 31, 5:15AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- There are more than 1,400 active reported Pharmaceutical-Biotech capital and maintenance (MRO) projects in North America, representing a total investment value (TIV) of nearly $62 billion. According to a recent analysis of Industrial Info's Pharmaceutical-Biotech Industry database, the Mid-Atlantic region is at the top of that investment, accounting for an $8.5 billion portion of that spending divided over 176 projects.
UTHR: 125.11 (+0.90)
Apple CEO publicly acknowledges that he's gay
By MAE ANDERSON - AP - Thu Oct 30, 6:59PM CDT
NEW YORK (AP) — Apple CEO Tim Cook's declaration that he's "proud to be gay" wasn't exactly news in Silicon Valley, where his sexual orientation was no secret. But advocates say that given Apple's immense reach and visibility, his coming-out could help change attitudes in workplaces across America.
UTHR: 125.11 (+0.90), AEO: 12.42 (-0.52), AAPL: 108.95 (-0.06)
United Therapeutics Falls on Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:02AM CDT
United Therapeutics Corporation (UTHR) incurred a third-quarter loss of 53 cents per share, missing the Zacks Consensus Estimate by a wide margin.
LCI: 51.53 (+1.36), MDT: 68.47 (+0.37), UTHR: 125.11 (+0.90), NVS: 92.52 (+0.76)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 15.92 (+14.33), BIIB: 325.66 (+4.91), AMRN: 0.84 (-0.06), UTHR: 125.11 (+0.90), NLNK: 33.72 (+1.57)
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 2.00% Loss
Comtex SmarTrend(R) - Tue Oct 28, 5:19PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 125.11 (+0.90)
Watch for United Therapeutics to Potentially Rebound After Falling 2.00% Yesterday
Comtex SmarTrend(R) - Tue Oct 28, 5:18PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 125.11 (+0.90)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 28, 12:26PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMKR: 6.38 (-0.01), XENT: 18.10 (+0.06), TRVN: 5.76 (-0.15), GLBZ: 12.40 (-0.08), SGMS: 12.61 (+0.22), ALIM: 5.00 (-0.06), UTHR: 125.11 (+0.90), SRPT: 16.17 (+0.05), WIRE: 40.57 (+0.18), REXX: 7.52 (-0.48), LMNX: 18.12 (+0.08)
United Therapeutics reports 3Q loss
Automated Insights - Tue Oct 28, 5:27AM CDT
SILVER SPRING, Md. (AP) _ United Therapeutics Corp. (UTHR) on Tuesday reported a third-quarter loss of $25.2 million.
UTHR: 125.11 (+0.90)
United Therapeutics Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 28, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2014.
UTHR: 125.11 (+0.90)
After Yesterday's Rally of 1.09% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Oct 22, 4:39PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $126.98 to a high of $131.44. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $128.69 on volume of 699,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 125.11 (+0.90)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 1.09% Gain
Comtex SmarTrend(R) - Wed Oct 22, 4:38PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $126.98 to a high of $131.44. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $128.69 on volume of 699,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 125.11 (+0.90)
United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014
PR Newswire - Tue Oct 21, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2014 financial results before market open on Tuesday, October 28, 2014.
UTHR: 125.11 (+0.90)
Creator of GeoStar and Sirius Radio, Martine Rothblatt to speak at the Church of Perpetual Life
PR Newswire - Mon Oct 20, 3:06PM CDT
Join the Church of Perpetual Life for a special presentation with Martine Rothblatt. She will be discussing the Terasem Movement which she launched in 2004. It is a transhumanist school of thought movement focused on promoting joy, diversity and the prospect of technological immortality via mind uploading and geoethical nanotechnology.
UTHR: 125.11 (+0.90)
Should Ebola Fear... Tobacco?
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 19, 11:15AM CDT
Source: Medicago In 2009, the Department of Defense's Defense Advanced Research Projects Agency, or DARPA, had a problem on its hands. The swine flu was spreading and policy makers were realizing that the current methods for producing vaccines...
RAI: 65.30 (+0.72), PM: 88.38 (+0.26), UTHR: 125.11 (+0.90), SRPT: 16.17 (+0.05), TKMR: 16.32 (-0.43), GSK: 45.20 (+0.29)
Upgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Thu Oct 16, 7:16AM CDT
United Therapeutics (NASDAQ:UTHR) was upgraded from Hold to Buy at Standpoint Research today. The stock closed yesterday at $124.04 on volume of 957,000 shares, below average daily volume of 1.1 million. Over the past year, United Therapeutics has traded in a range of $36.55 to $136.93 and closed yesterday at $124.04, 239% above that low. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 1.8%.
UTHR: 125.11 (+0.90)
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 13.24 (+0.22), UTHR: 125.11 (+0.90), PCRX: 88.02 (+2.00), HPTX: 21.54 (-0.28)
J&J Beats Q3 Earnings on Strong Drug Sales, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Oct 14, 10:27AM CDT
Johnson & Johnson's (JNJ) Pharmaceutical segment continued to deliver with new products like Olysio (HCV) putting in an impressive performance.
AGN: 195.82 (-0.18), JNJ: 108.70 (+0.50), SHPG: 200.51 (+1.93), UTHR: 125.11 (+0.90)
Shares of UTHR Up 39.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 09, 9:44AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 2 months, United Therapeutics has returned 39.74% as of today's recent price of $130.44.
UTHR: 125.11 (+0.90)
